These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28397579)

  • 1. Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Ciampi E; Uribe-San-Martín R; Godoy-Santín J; Cruz JP; Cárcamo-Rodríguez C; Juri C
    Mult Scler; 2017 Nov; 23(13):1791-1795. PubMed ID: 28397579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levetiracetam-responding paroxysmal nonkinesigenic dyskinesia.
    Alemdar M; Iseri P; Selekler M; Komsuoğlu SS
    Clin Neuropharmacol; 2007; 30(4):241-4. PubMed ID: 17762321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia.
    Löscher W; Richter A
    Eur J Pharmacol; 2000 Mar; 391(3):251-4. PubMed ID: 10729365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Pop R; Kipfer S
    Mult Scler; 2017 Nov; 23(13):1795-1797. PubMed ID: 28397578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxysmal dystonia and paroxysmal tremor in a young patient with multiple sclerosis.
    Nardocci N; Zorzi G; Savoldelli M; Rumi V; Angelini L
    Ital J Neurol Sci; 1995 Jun; 16(5):315-9. PubMed ID: 8537220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxysmal dystonia with thalamic lesion in multiple sclerosis.
    Zenzola A; De Mari M; De Blasi R; Carella A; Lamberti P
    Neurol Sci; 2001 Oct; 22(5):391-4. PubMed ID: 11917977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemiballismus in subthalamic haemorrhage: efficacy of levetiracetam.
    Marchione P; Vento C; Marianetti M; Romeo T; Amabile GA; Giacomini P
    Eur J Neurol; 2009 Jun; 16(6):e112-3. PubMed ID: 19453693
    [No Abstract]   [Full Text] [Related]  

  • 8. Phenotypic characterization of PIGN-associated paroxysmal dyskinesia in Soft-coated wheaten terriers and preliminary response to acetazolamide therapy.
    Packer RA; Wachowiak I; Thomovsky SA; Berg J; Vasquez L; O'Brien DP
    Vet J; 2021 Mar; 269():105606. PubMed ID: 33593494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of paroxysmal ataxia and dysarthria in multiple sclerosis with levetiracetam.
    Goodwin SJ; Carpenter AF
    Mult Scler Relat Disord; 2016 Nov; 10():79-81. PubMed ID: 27919504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Paroxysmal dystonia and multiple sclerosis].
    El Otmani H; Benmansour Y; Araqi-Houssaini A; Benkirane N; Dany F; Abdoh Rafai M; El Moutawakil B; Slassi I
    Rev Neurol (Paris); 2014 Feb; 170(2):119-23. PubMed ID: 24267950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with acetazolamide of brain-stem and spinal paroxysmal disturbances in multiple sclerosis.
    Voiculescu V; Pruskauer-Apostol B; Alecu C
    J Neurol Neurosurg Psychiatry; 1975 Feb; 38(2):191-3. PubMed ID: 1151400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levetiracetam for phasic spasticity in multiple sclerosis.
    Hawker K; Frohman E; Racke M
    Arch Neurol; 2003 Dec; 60(12):1772-4. PubMed ID: 14676055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxysmal movement disorders.
    Waln O; Jankovic J
    Neurol Clin; 2015 Feb; 33(1):137-52. PubMed ID: 25432727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Movement disorders in multiple sclerosis and neuromyelitis optica: A clinical marker of neurological disability.
    Candeias da Silva C; Bichuetti DB; Azevedo Silva SMC; Ferraz HB; Oliveira EML; Borges V
    Parkinsonism Relat Disord; 2018 Jun; 51():73-78. PubMed ID: 29530725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis.
    Falah M; Madsen C; Holbech JV; Sindrup SH
    Eur J Pain; 2012 Jul; 16(6):860-9. PubMed ID: 22337561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and management of acute movement disorders.
    Dressler D; Benecke R
    J Neurol; 2005 Nov; 252(11):1299-306. PubMed ID: 16208529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxysmal exertion-induced dystonia secondary to Erdheim-Chester disease.
    Baldacci F; Lucetti C; Vergallo A; Borelli P; Tessa C; Viacava P; Bonuccelli U
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1105-6. PubMed ID: 22980524
    [No Abstract]   [Full Text] [Related]  

  • 18. Acetazolamide treatment of paroxysmal dystonia in central demyelinating disease.
    Sethi KD; Hess DC; Huffnagle VH; Adams RJ
    Neurology; 1992 Apr; 42(4):919-21. PubMed ID: 1565252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalamocortical dysconnectivity in paroxysmal kinesigenic dyskinesia: Combining functional magnetic resonance imaging and diffusion tensor imaging.
    Long Z; Xu Q; Miao HH; Yu Y; Ding MP; Chen H; Liu ZR; Liao W
    Mov Disord; 2017 Apr; 32(4):592-600. PubMed ID: 28186667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.
    Fröhlich K; Winder K; Linker RA; Huhn K; Engelhorn T; Dörfler A; Lee DH; Schwab S; Seifert F
    J Neurol; 2018 Oct; 265(10):2277-2283. PubMed ID: 30066284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.